A mixed performance in the stock price over the year has left investors unsure of what to expect, resulting in a range of outlooks from optimistic to pessimistic. This year’s metric has recorded a Price increase of 64.50%. However, over the past six months, we’ve seen a weaker performance of 8.88%. The price of MREO fallen by 2.15% over the last 30 days. And in the last five days, it has surged by 11.76%.
Mereo Biopharma Group Plc ADR experienced a rather steady stock market performance.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
52-week price history of MREO Stock
Examining the 52-week high and low prices can provide valuable insights into a stock’s current status and future performance. Mereo Biopharma Group Plc ADR’s current trading price is -24.10% away from its 52-week high, while its distance from the 52-week low is 77.21%. The stock’s price range during this time has been between $2.15 and $5.02. The trading volume for the Healthcare sector company’s shares reached about 1.48 million for the day, which was higher than the average daily volume of 0.78 million over the last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Mereo Biopharma Group Plc ADR (MREO) has experienced a quarterly decline of -5.00% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 587.97M and boasts a workforce of 33 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
MREO’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for MREO stands at 0.09. Similarly, the long-term debt-to-equity ratio is also 0.01.
MREO Stock Stochastic Average
Today’s raw stochastic average for Mereo Biopharma Group Plc ADR over the last 50 days is 43.48%.This indicates a decrease from the raw stochastic average of the past 20 days, which was 84.34%. Moreover, the company’s Stochastic %K and %D values for the last 20 days were 49.00% and 29.20%, respectively.
